| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| AMG-420 | BI-836909; AMG-420,BI836909 | Phase Ⅰ | Micromet, Boehringer Ingelheim, Amgen | Multiple myeloma (MM) | Details |
| TNB-383B | TNB-383B; TNB383B | Phase Ⅰ | Teneobio, Abbvie | Multiple myeloma (MM) | Details |
| LCAR-B38M cell product | JNJ-4528; JNJ-68284528; LCAR-B38M, JNJ 4528 | Phase Ⅱ | Nanjing Chuanqi Biotech, Janssen | Multiple myeloma (MM) | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase Ⅰ | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple myeloma (MM) | Details | |
| BCMA-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology) | IND Filing | Unicar-Therapy Bio-medicine Technology | Multiple myeloma (MM) | Details | |
| GSK-2857916 | GSK-2857916; J6M0-mcMMAF | Phase Ⅱ | GlaxoSmithKline | Multiple myeloma (MM) | Details |
| Idecabtagene vicleucel | bb-2121 | Phase Ⅲ | bluebird bio, Celgene | Multiple myeloma (MM) | Details |
| CART-BCMA | CART-BCMA; MTV-273,CART BCMA,MTV273 | Phase Ⅰ | University of Pennsylvania, Novartis | Multiple myeloma (MM) | Details |
| P-BCMA-101 | P-BCMA-101,P-BCMA101 | Phase Ⅰ | Poseida Therapeutics | Multiple myeloma (MM) | Details |
| BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) | Phase Ⅱ | Asclepius Technology Company Group | Multiple myeloma (MM) | Details | |
| Human BCMA chimeric antigen receptor autologous T cell（Nanjing Reindeer Medical Technology） | CT103A | IND Filing | Innovent Biologics, Nanjing Reindeer Medical Technology | Multiple myeloma (MM) | Details |
| MEDI-2228 | MEDI-2228,MEDI 2228,MEDI2228 | Phase Ⅰ | MedImmune | Multiple myeloma (MM) | Details |
| SEA-BCMA | SEA-BCMA; SGN-BCMA | Phase Ⅰ | Seattle Genetics | Multiple myeloma (MM) | Details |
| bb-21217 | bb-21217,bb 21217,bb21217 | Phase Ⅰ | bluebird bio, Celgene | Multiple myeloma (MM) | Details |
| KITE-585 | KITE-585,KITE585 | Phase Ⅰ | Kite Pharma, National Cancer Institute | Multiple myeloma (MM) | Details |
| PF-06863135 | PF-06863135,PF 06863135 | Phase Ⅰ | Pfizer | Multiple myeloma (MM) | Details |
| LCAR-B4822M | LCAR-B4822M,LCAR B4822M,LCARB4822M | Phase Ⅰ | GenScript Biotech Corporation | Multiple myeloma (MM) | Details |
| CAR-BCMA T cell therapy | CT-053-CARsgen | Phase Ⅰ | CARsgen Therapeutics | Multiple myeloma (MM) | Details |
| Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) | BCMA-CART | Phase Ⅰ | Shanghai Hrain Biotechnology | Multiple myeloma (MM) | Details |
| JNJ-64007957 | JNJ-7957; JNJ-64007957; JNJ-64007959 | Phase Ⅰ | Janssen, Genmab | Multiple myeloma (MM) | Details |
| AUTO-2 | AUTO-2; SUB-96123,AUTO 2; SUB 96123 | Phase Ⅱ | Autolus | Multiple myeloma (MM) | Details |
| CC-93269 | CC-93269; EM-901 | Phase Ⅰ | Celgene | Multiple myeloma (MM) | Details |
| ACTR 087/SEA BCMA combination therapy | Phase Ⅰ | Unum Therapeutics, Seattle Genetics | Multiple myeloma (MM) | Details | |
| anti-BCMA CAR T-cell Therapy (Juno Therapeutics) | ET-140; ET140-CAR; JCARH-125; FCARH-143,FCARH143,MCARH171 | Phase Ⅱ | Juno Therapeutics | Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas | Details |
| ALLO-715 | ALLO-715 | Phase Ⅰ | Allogene Therapeutics, Cellectis | Multiple myeloma (MM) | Details |
| Belantamab mafodotin | GSK-2857916; GSK2857916 | Phase Ⅰ | GlaxoSmithKline | Multiple myeloma (MM) | Details |
| BCBM CAR T cell (Pregene) | Phase Not Specified | Pregene, BioCast | Multiple myeloma (MM) | Details |
This web search service is supported by Google Inc.
A-Z
